Alpha-Mannosidosis Clinical Trial
Official title:
Clinical Biomarkers in Alpha-Mannosidosis
Verified date | November 29, 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Alpha-mannosidosis is a rare inherited disorder. It causes problems in many organs and
tissues of the body. It can occur in children and adults. Because there is no treatment for
this disease, researchers want to find out more about it.
Objective:
- To learn more about Alpha-mannosidosis.
Eligibility:
- People ages 5-60 with Alpha-mannosidosis.
Design:
- Participants will be recruited from patient support organizations and medical genetics
clinics.
- Participants will have 3 study visits, about once a year. A final evaluation will be
made after 3 years.
- Participants will have a medical history and a physical exam.
- Blood samples and a urine sample will be collected.
- Cerebrospinal fluid will be collected. A small area of the lower back will be numbed
with medicine. A thin needle will be inserted between the spine bones. About 2
tablespoons of spinal fluid will be removed.
- Brain magnetic resonance spectroscopy (MRS) scans will be done at each visit. MRS uses a
strong magnetic field and radio waves to take pictures of chemicals in the brain with a
scanner. The participant will lie on a table that can slide in and out of the cylinder.
While in the scanner the participant will hear loud knocking noises. They will get
earplugs or earmuffs to muffle the sound. Medicines might be used to keep the
participant asleep during the MRS.
- Participants will have a skin biopsy at the first visit only. A small area of the
participant s skin will be numbed. A small circle of skin will be removed with a biopsy
tool.
Status | Completed |
Enrollment | 11 |
Est. completion date | November 29, 2019 |
Est. primary completion date | November 29, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 60 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Must have a verifiable diagnosis of AMD based on clinical, biochemical and/or molecular grounds, including increased urinary excretion of mannose-rich oligosaccharides, decreased acidic -mannosidase activity in leukocytes or other nucleated cells, and/or mutations in two alleles of the LAMAN gene. 2. Must be at least five years old. EXCLUSION CRITERIA: 1. Significant systemic or major disease including congestive heart failure, coronary artery disease, cerebrovascular disease and pre-existing or recent onset pulmonary disease, renal failure, organ transplantation, decompensated liver disease, serious psychiatric disease, or malignancy that in the opinion of the investigator would preclude successful participation.. 2. Pregnancy. We will perform a urine pregnancy test on all post-menarcheal female subjects on the same day as the history and physical exam, prior to MRI. If pregnancy is identified, we will follow Maryland state law in place at the time concerning parental notification. In the event a woman becomes pregnant during the study, she will be withdrawn from all study procedures, but the study team will follow up with the participant regarding the pregnancy outcome. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Magnitsky S, Vite CH, Delikatny EJ, Pickup S, Wehrli S, Wolfe JH, Poptani H. Magnetic resonance spectroscopy of the occipital cortex and the cerebellar vermis distinguishes individual cats affected with alpha-mannosidosis from normal cats. NMR Biomed. 2010 Jan;23(1):74-9. doi: 10.1002/nbm.1430. — View Citation
Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis. 2008 Jul 23;3:21. doi: 10.1186/1750-1172-3-21. Review. — View Citation
Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, Hixson KK, Lipton MS, Camp DG, Coyle PK, Smith RD, Bergquist J. Establishing the proteome of normal human cerebrospinal fluid. PLoS One. 2010 Jun 11;5(6):e10980. doi: 10.1371/journal.pone.0010980. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify cerebrospinal fluid biomarkers that could serve as candidate surrogate markers of treatment effect in a future clinical trial. | Identify cerebrospinal fluid biomarkers that could serve as candidate surrogate markers of treatment effect in a future clinical trial. | Baseline | |
Secondary | Establish reliable clinical benchmarks for alpha-mannosidosis. | Establish reliable clinical benchmarks for alpha-mannosidosis. | Ongoing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Not yet recruiting |
NCT06184503 -
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
|
||
Completed |
NCT01908725 -
Lamazym Aftercare Study
|
Phase 3 | |
Recruiting |
NCT02171104 -
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
|
Phase 2 | |
Completed |
NCT01681940 -
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
|
Phase 2 | |
Withdrawn |
NCT04031066 -
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
|
Phase 3 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02478840 -
Evaluation of Long-term Efficacy of Treatment With Lamazym
|
Phase 3 | |
Completed |
NCT02998879 -
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
|
Phase 2 | |
Completed |
NCT01908712 -
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
|
Phase 3 | |
Completed |
NCT01681953 -
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
|
Phase 3 | |
Terminated |
NCT01372228 -
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
|
Phase 1/Phase 2 | |
Available |
NCT04959240 -
Expanded Access to Velmanase Alfa
|